Register for our S/EIS Fund

In this truly global Christmas special o2h ChaiTime we invited some of the most experienced drug hunters on the planet. Sunil Shah quizzed the panelists with questions around Hit Finding, technologies that we have used or have been successful in creating chemical matter, how CRO’s can have a big impact on drug discovery projects, similarities/differences between Big Pharma and Start up in approaches to drug hunting, and many more.

The panelists
Peter Hamley Chief Scientific Officer at Samsara Therapeutics

Peter is a recognized industry leader in drug discovery, having spent 15 years at Sanofi, most recently as Global Head of External Innovation, Drug Discovery.

Christopher Smith Senior Director at Mirati Therapeutics

Chris is a medicinal chemist with over 20 years experience as a Entrepreneurial Drug Discovery leader with a track record of leading multiple drug discovery projects from hit identification to IND.

Hemal Soni Head of Chemistry at o2h Discovery

Hemal is the Head of the PR&D at o2h discovery and is spearheading the chemistry team of ~200 chemists having led projects with many USA, UK, EU and Japanese biotech and pharma collaborators around the world.

Karin Briner Vice President at Novartis

Dr. Briner is a medicinal chemist and Dr. Briner joined Novartis as Global Head of GDC in June 2011. She is a member of the senior leadership team of NIBR and has responsibilities for discovery chemistry research across all disease areas; this includes research groups in Cambridge MA, Basel Switzerland, Emeryville CA, and Shanghai.

Sunil Shah CEO at o2h Group

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector

Register for Invitations